OTLK | Outlook Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.17 - 5.44
52 Week Range	4.61 - 12.85
Beta	-0.16
Implied Volatility	169.62%
IV Rank	35.85%
Day's Volume	137,605
Average Volume	264,387
Shares Outstanding	23,655,600
Market Cap	124,901,568
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-06-14

Valuation
Profitability
Growth
Health
P/E Ratio	-0.90
Forward P/E Ratio	N/A
EPS	-5.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	24
Country	USA
Website	OTLK

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK's peers: CKPT, MBIO, RVPH, FBIOP, KOD, OCUP, PLX, EYPT, SLS, EYEN, CDTX, FBIO, SELB, XFOR, INZY, TERN, DAWN, HOOK, HRTX, GRTX

*Chart delayed

Analyzing fundamentals for OTLK we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see OTLK Fundamentals page.

Watching at OTLK technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on OTLK Technicals page.